Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy
Publication
, Journal Article
Tambaro, FP; Khazal, S; Nunez, C; Ragoonanan, D; Tewari, P; Petropoulos, D; Kebriaei, P; Wierda, WG; Mahadeo, KM
Published in: Clinical Case Reports
September 1, 2020
The T-cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T-cell therapy.
Duke Scholars
Published In
Clinical Case Reports
DOI
EISSN
2050-0904
Publication Date
September 1, 2020
Volume
8
Issue
9
Start / End Page
1678 / 1681
Related Subject Headings
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 30 Agricultural, veterinary and food sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Tambaro, F. P., Khazal, S., Nunez, C., Ragoonanan, D., Tewari, P., Petropoulos, D., … Mahadeo, K. M. (2020). Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy. Clinical Case Reports, 8(9), 1678–1681. https://doi.org/10.1002/ccr3.2918
Tambaro, F. P., S. Khazal, C. Nunez, D. Ragoonanan, P. Tewari, D. Petropoulos, P. Kebriaei, W. G. Wierda, and K. M. Mahadeo. “Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy.” Clinical Case Reports 8, no. 9 (September 1, 2020): 1678–81. https://doi.org/10.1002/ccr3.2918.
Tambaro FP, Khazal S, Nunez C, Ragoonanan D, Tewari P, Petropoulos D, et al. Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy. Clinical Case Reports. 2020 Sep 1;8(9):1678–81.
Tambaro, F. P., et al. “Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy.” Clinical Case Reports, vol. 8, no. 9, Sept. 2020, pp. 1678–81. Scopus, doi:10.1002/ccr3.2918.
Tambaro FP, Khazal S, Nunez C, Ragoonanan D, Tewari P, Petropoulos D, Kebriaei P, Wierda WG, Mahadeo KM. Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy. Clinical Case Reports. 2020 Sep 1;8(9):1678–1681.
Published In
Clinical Case Reports
DOI
EISSN
2050-0904
Publication Date
September 1, 2020
Volume
8
Issue
9
Start / End Page
1678 / 1681
Related Subject Headings
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 30 Agricultural, veterinary and food sciences